Evidence map›Paper›PMID 42511816›Full record

ReviewInternational journal of molecular sciences2026

PCSK9 as a Potential Regulator of Endothelial Dysfunction: Mechanistic Insights and Future Directions.

Anisa Qisti Mathriul, Maharani Hestu Mukti Wisesa, Vicko Suswidiantoro, Meidi Utami Puteri, Mitsuyasu Kato, Fadlina Chany Saputri

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anisa Qisti MathriulFaculty of Pharmacy, Universitas Indonesia, UI Depok Campus, Depok 16424, West Java, Indonesia.
Maharani Hestu Mukti WisesaFaculty of Pharmacy, Universitas Indonesia, UI Depok Campus, Depok 16424, West Java, Indonesia.
Vicko SuswidiantoroFaculty of Pharmacy, Universitas Indonesia, UI Depok Campus, Depok 16424, West Java, Indonesia.ORCID 0000-0002-6315-706X
Meidi Utami PuteriLaboratory of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok 16424, West Java, Indonesia.ORCID 0000-0003-1550-8627
Mitsuyasu KatoFaculty of Pharmacy, Universitas Indonesia, UI Depok Campus, Depok 16424, West Java, Indonesia.ORCID 0000-0001-9905-2473
Fadlina Chany SaputriLaboratory of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI, Depok 16424, West Java, Indonesia.ORCID 0000-0002-6668-8915

Funding

Indonesia Endowment Fund for Education the EQUITY Program (Contract Nos. 4302/B3/DT.03.08/2025 and 573/PKS/R/UI/2025)University of Indonesia the PUTI Q2 2023 research grant (Contract Number: PKS-55/UN2.RST/HKP.05.00/2025)
6 · The paper itself

Abstract

The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and its role in promoting the degradation of the low-density lipoprotein receptor (LDLR) has revolutionized lipid-lowering therapy, offering new therapy for patients with hypercholesterolemia. Notably, PCSK9 is now being explored for functions beyond lipid regulation. Emerging evidence implicates PCSK9 in vascular pathology by influencing endothelial dysfunction, inflammatory signaling, oxidative stress, and vascular homeostasis-potentially through LDLR-independent mechanisms. This review critically evaluates PCSK9's potential as a regulator of endothelial dysfunction, synthesizing findings from

Indexed as

Endothelium, VascularProprotein Convertase 9AnimalsCardiovascular DiseasesHumansOxidative StressPCSK9 InhibitorsSignal TransductionPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9endothelial dysfunctionexperimental and clinical evidenceoxidative stressPCSK9vascular inflammation

Identifiers

PMID42511816
PMCPMC13410133

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.